Jascayd (Nerandomilast)

Nerandomilast is a medicine for lung scarring diseases called pulmonary fibrosis. It is taken as a pill by mouth. It works by blocking an enzyme involved in inflammation and scarring, which helps slow down how fast the lungs get stiffer.

Brand names:Jascayd
Medication

What people taking Jascayd (Nerandomilast) report

Every report comes from a Lived member, sent anonymously.

Have you tried Jascayd (Nerandomilast) for Idiopathic Pulmonary Fibrosis?

NameHow it went

About Jascayd (Nerandomilast)

What It's For

Nerandomilast, sold as Jascayd, is a prescription tablet for adults with pulmonary fibrosis, a group of lung diseases in which the tissue deep in the lungs becomes scarred, thick and stiff over time. As the scarring spreads, breathing becomes harder and the blood may not pick up enough oxygen. It is approved for two situations. Idiopathic pulmonary fibrosis (IPF) is scarring with no identifiable cause. Progressive pulmonary fibrosis (PPF) describes other scarring lung diseases that keep getting worse despite usual care, such as scarring linked to an autoimmune disease or to an immune reaction to molds, dusts or other particles breathed in over time. The FDA first approved it in 2025, making it a newer option alongside the two established antifibrotic medicines, nintedanib and pirfenidone. It can be taken on its own or together with one of them. It has not been studied in children.

How It Works

Lung scarring is driven partly by ongoing inflammation and by signals that tell connective tissue cells to lay down more scar. Inside cells, a messenger molecule called cyclic AMP helps keep these signals in check, and an enzyme called phosphodiesterase 4 (PDE4) breaks that messenger down. Nerandomilast blocks PDE4, acting mostly on one particular form of the enzyme, so cyclic AMP stays higher for longer. In laboratory studies this reduces the production of inflammatory and scar-promoting growth signals. The practical result is a slower loss of lung function rather than repair. Nerandomilast does not remove scar tissue that is already there.

Dosage & Administration

The usual dose is one 18 mg tablet twice a day, roughly 12 hours apart, with or without food. If side effects such as diarrhea are hard to tolerate, the prescriber may lower it to 9 mg twice a day. The lower dose is also used when someone needs a medicine that raises nerandomilast levels (see Interactions & Warnings). People who also take pirfenidone should stay on 18 mg, because the 9 mg dose did not work in that combination. Tablets are swallowed whole. For people who have trouble swallowing, a tablet can be placed uncrushed in a glass of about 3 to 4 ounces of plain, room-temperature water and stirred for 15 to 20 minutes until it breaks into small pieces; the mixture is drunk within 2 hours, and the glass is rinsed with more water and that is drunk too so the full dose is taken. If a dose is missed, skip it and take the next one at the usual time rather than doubling up.

Side Effects

Diarrhea is the most common side effect. In the IPF trial it affected about 4 in 10 people on the 18 mg dose compared with fewer than 2 in 10 on placebo, and it was more frequent in people also taking nintedanib, which causes diarrhea on its own. It was usually mild to moderate and tended to start in the first three months. Lower appetite, weight loss, nausea, tiredness, headache and dizziness are also reported. Unintended weight loss is worth tracking, since it can matter for strength and breathing. Low mood deserves attention. Depression-related events, including suicidal thoughts, were reported somewhat more often with nerandomilast than with placebo, and people with severe depression or a history of suicidal thoughts were excluded from the trials. New or worsening depression, or any thoughts of self-harm, should be raised with the care team promptly. Less common findings in the trials included inflamed blood vessels (vasculitis), an irregular heart rhythm called atrial fibrillation, and a small excess of new cancers, including skin cancers, compared with placebo. These were uncommon, and it is not yet clear whether all of them are caused by the drug, but they are a reason for routine follow-up.

Interactions & Warnings

Nerandomilast is cleared mainly by a liver enzyme called CYP3A, so medicines that speed up or slow down that enzyme change how much of it stays in the body. Strong enzyme speeders, such as the seizure medicine carbamazepine, can cut levels enough to make it less effective and should be avoided. Strong enzyme blockers, such as the antifungal itraconazole, raise levels and call for the 9 mg dose. Because these effects are easy to miss, the prescriber and pharmacist should see a full list of medicines and supplements, including anything started by another clinician. Pirfenidone also lowers nerandomilast levels, which is why the dose stays at 18 mg in that combination. In animal studies, nerandomilast increased pregnancy loss. There are no human pregnancy data, and it is not known whether it passes into breast milk. Anyone who could become pregnant should discuss this before starting and tell the prescriber right away if pregnancy is suspected. It is not recommended for people with severe liver disease or kidney failure.

What to Expect

Nerandomilast does not make breathing easier in a way people usually feel. Its benefit shows up on lung function testing, mainly forced vital capacity (FVC), the amount of air a person can blow out after a full breath. FVC tends to fall over time in pulmonary fibrosis. In the main one-year trials it still fell with nerandomilast, but by less: in IPF, the decline was about 106 mL on the 18 mg dose versus about 170 mL on placebo. The trials did not show a clear reduction in sudden flare-ups or hospital stays. In PPF fewer deaths were seen, though this finding needs confirmation. Treatment is typically ongoing, with regular breathing tests to see how lung function is changing and visits to review diarrhea, weight and mood. Pulmonary fibrosis has no cure, so this medicine is one part of care that can also include pulmonary rehabilitation, oxygen when needed and, for some people, evaluation for lung transplant.

Questions to Ask Your Doctor

  1. 1.Should I take nerandomilast on its own or alongside nintedanib or pirfenidone, and what would each choice mean for side effects?
  2. 2.How will we judge from my breathing tests whether it is helping?
  3. 3.What should I do if diarrhea or weight loss becomes a problem, and when would we lower the dose?
  4. 4.Do any of my current medicines or supplements change how nerandomilast works?
  5. 5.How will we keep an eye on my mood while I take it?

Last reviewed • Oct 2026

Educational content, not medical advice.